Torben Joergensen - Biotage AB President and CEO
CEO
Mr. Torben Joergensen no longer serves as President and Chief Executive Officer of Biotage AB, effective as of November 6, 2019. He has held the position since April 27, 2006. He was Director of the Company since April 24, 2019. Prior to that, he held corresponding positions at Affibody, KaroBio and the Danish diagnostic company, DAKO since 2019.
| Age | 66 |
| Tenure | 5 years |
| Phone | 46 18 56 59 00 |
| Web | https://www.biotage.com |
Biotage AB Management Efficiency
The company has return on total asset (ROA) of 0.109 % which means that it generated a profit of $0.109 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1785 %, meaning that it generated $0.1785 on every $100 dollars invested by stockholders. Biotage AB's management efficiency ratios could be used to measure how well Biotage AB manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 150 M in total debt with debt to equity ratio (D/E) of 0.16, which may suggest the company is not taking enough advantage from borrowing. Biotage AB has a current ratio of 2.38, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Biotage AB until it has trouble settling it off, either with new capital or with free cash flow. So, Biotage AB's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biotage AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biotage to invest in growth at high rates of return. When we think about Biotage AB's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 3 records | CEO Age | ||
| Michael Farrell | ResMed Inc | 48 | |
| Gary Guthart | Intuitive Surgical | 58 | |
| Anthony Hunt | Repligen | 60 | |
Management Performance
| Return On Equity | 0.18 | |||
| Return On Asset | 0.11 |
Biotage AB Leadership Team
Elected by the shareholders, the Biotage AB's board of directors comprises two types of representatives: Biotage AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biotage. The board's role is to monitor Biotage AB's management team and ensure that shareholders' interests are well served. Biotage AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biotage AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Karolina Lawitz, Member of the Board of Directors | ||
| NilsOlof Bjork, Director | ||
| Love Amcoff, Director, Employee Representative | ||
| Thomas Eklund, Member of the Board of Directors | ||
| Rikke Rytter, Vice President Global Marketing | ||
| Mark Bradley, Director | ||
| Ove Mattsson, Chairman of the Board of Directors | ||
| Cecilia Hallner, Global Human Resources Director | ||
| Malin Albertsson, Director, Employee Representative | ||
| Erika Johnson, CFO | ||
| Petra Duprez, Chief Officer | ||
| Jonas Stahlberg, Chief Auditor | ||
| Raffaella Bombarda, EVP Marketing | ||
| Yvonne Martensson, Director | ||
| Steve Jordan, Chief Scientific Officer | ||
| Anders Wikstrom, Vice President - Operations | ||
| Lars Backman, Vice President of Corporate Development | ||
| Anders Walldov, Member of the Board of Directors | ||
| Scott Carr, Pres Americas | ||
| Tomas Blomquist, CEO Pres | ||
| Peter Ehrenheim, Member of the Board of Directors | ||
| Torben Joergensen, President and CEO | ||
| Maja Nilsson, Chief Officer | ||
| CS BSc, Ex Operations | ||
| Paul Belton, Vice President - Business Development | ||
| JonSverre Schanche, Chief Officer | ||
| Olof Nord, Exec Devel | ||
| Lars LLB, Chief Officer | ||
| Annika Gardlund, Director, Employee Representative |
Biotage Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Biotage AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.16 % | |||
| Current Valuation | 1.17 B | |||
| Shares Outstanding | 65.98 M | |||
| Shares Owned By Insiders | 0.58 % | |||
| Shares Owned By Institutions | 64.57 % | |||
| Price To Earning | 47.58 X | |||
| Price To Book | 6.36 X | |||
| Price To Sales | 6.61 X |
Pair Trading with Biotage AB
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biotage AB position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biotage AB will appreciate offsetting losses from the drop in the long position's value.Moving together with Biotage OTC Stock
| 0.75 | GOOG | Alphabet Class C Buyout Trend | PairCorr |
Moving against Biotage OTC Stock
| 0.77 | MCD | McDonalds Financial Report 25th of July 2024 | PairCorr |
| 0.69 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
| 0.66 | BA | Boeing Financial Report 24th of July 2024 | PairCorr |
| 0.57 | INTC | Intel Financial Report 25th of July 2024 | PairCorr |
| 0.45 | HD | Home Depot Financial Report 21st of May 2024 | PairCorr |
The ability to find closely correlated positions to Biotage AB could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biotage AB when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biotage AB - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biotage AB to buy it.
The correlation of Biotage AB is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biotage AB moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biotage AB moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biotage AB can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biotage AB. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Biotage AB information on this page should be used as a complementary analysis to other Biotage AB's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for Biotage OTC Stock analysis
When running Biotage AB's price analysis, check to measure Biotage AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotage AB is operating at the current time. Most of Biotage AB's value examination focuses on studying past and present price action to predict the probability of Biotage AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotage AB's price. Additionally, you may evaluate how the addition of Biotage AB to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |